Labiana Health S.A. is a Spain-based pharmaceutical holding company specializing in the development, manufacturing, and marketing of medicines for both animal and human health. It offers a diverse portfolio including anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, vitamins, and sterile, lyophilized, and biological formats. Notable own-brand products feature Fosfomycin Trometamol under Fosfomicina Labiana for urinary infections. The company provides contract development and manufacturing organization (CDMO) services, regulatory support for global product registrations, and expertise in galenic, analytical, and formulation development, including bacterial vaccines. Operating through subsidiaries like Veterinarski Zavod Subotica in Serbia for biologicals and vaccines, and Zoleant Pharmaceuticals International in Turkey for niche generics and feed additives, it serves markets in Spain, the European Union, North America, and over 150 countries worldwide. With six production plants in Spain and Serbia, Labiana Health S.A. supports livestock productivity, human therapeutics, and the 'One Health' principle linking animal, human, and environmental well-being. Founded in 1958 and headquartered in Pozuelo de Alarcón, Madrid, it stands as a key player in veterinary pharmaceuticals and human sterile forms.
Leadership (8)
Michael EgholmPresident, Chief Executive Officer & Director
Anders DavasSenior Vice President of Global Operations
Hanjoon KimChief Financial Officer
Jonathan MickelsenVice President & Chief Accounting Officer
Sean MackayChief Business Officer & Senior Vice President
Elizabeth R. JensenChief Human Resources Officer
Mike MusgnugSenior Vice President & Chief Commercial Officer
John GrazianoVice President of Investor Relations